Ellagic Acid Prevents Myocardial Infarction-induced Left Ventricular Diastolic Dysfunction in Ovariectomized Rats

Regulation of redox enzymes by nutraceuticals: a review of the roles of antioxidant polyphenols and peptides

Redox enzymes are essential components of the cellular defence system against oxidative stress, which is a common factor in various diseases. Therefore, understanding the role of bioactive nutraceuticals in modulating the activity of these enzymes holds immense therapeutic potential. This paper provides a comprehensive review of the regulation of redox enzymes in cell and animal models by food-derived bioactive nutraceuticals, focusing on polyphenols and peptides. Specifically, this paper discusses the regulation of superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT), NAPDH oxidase, xanthine oxidase (XO), myeloperoxidase (MPO), and haem oxygenase (HO) in cell and animal models. Polyphenols, which are abundant in fruits, vegetables, and beverages, have diverse antioxidant properties, including direct scavenging of reactive oxygen species and regulation of transcription factors such as nuclear factor erythroid 2-related factor 2, which leads to the increased expression of the redoxenzymes SOD, HO, and GPx. Similarly, bioactive peptides from various food proteins can enhance antioxidative enzyme activity by regulating gene expression and directly activating the enzyme CAT. In other cases, an antioxidative response requires the downregulation or inhibition of the redox enzymes XO, MPO, and NAPDH oxidase. This paper highlights the potential of bioactive nutraceuticals in mitigating oxidative stress-related diseases and their mechanisms in modulating the redox enzyme expression or activity. Furthermore, the review highlights the need for further research to uncover new therapeutic strategies using nutraceuticals for enhancing cellular antioxidant defence mechanisms and improving health outcomes.

Molecular mechanisms involved in therapeutic effects of natural compounds against cisplatin-induced cardiotoxicity: a review

Cisplatin is a widely used chemotherapeutic agent for the treatment of various cancers. However, the clinical use of cisplatin is limited by its cardiotoxic side effects. The primary mechanisms implicated in this cardiotoxicity include mitochondrial dysfunction, oxidative stress, inflammation, and apoptotic. Numerous natural compounds (NCs) have been introduced as promising protective factors against cisplatin-mediated cardiac damage. The current review summarized the potential of various NCs as cardioprotective agents at the molecular levels. These compounds exhibited potent antioxidant and anti-inflammatory effects by interaction with the PI3K/AKT, AMPK, Nrf2, NF-κB, and NLRP3/caspase-1/GSDMD pathways. Generally, the modulation of these signaling pathways by NCs represents a promising strategy for improving the therapeutic index of cisplatin by reducing its cardiac side effects.

Strength training improves heart function, collagen and strength in rats with heart failure

BACKGROUND/OBJECTIVES

Myocardial infarction (MI) frequently leads to cardiac remodeling and failure with impaired life quality, playing an important role in cardiovascular deaths. Although physical exercise is a well-recognized effective non-pharmacological therapy for cardiovascular diseases, the effects of strength training (ST) on the structural and functional aspects of cardiac remodeling need to be further documented. In this study, we aimed to investigate the role of a linear block ST protocol in the rat model of MI.

METHODS AND RESULTS

After 6 weeks of MI induction or sham surgery, male adult rats performed ST for the following 12 weeks. The ladder-based ST program was organized in three mesocycles of 4 weeks, with one load increment for each block according to the maximal carrying load test. After 12 weeks, the infarcted-trained rats exhibited an increase in performance, associated with reduced cardiac hypertrophy and pulmonary congestion compared with the untrained group. Despite not changing MI size, the ST program partially prevented cardiac dilatation and ventricular dysfunction assessed by echocardiography and hemodynamics, and interstitial fibrosis evaluated by histology. In addition, isolated cardiac muscles from infarcted-trained rats had improved contractility parameters in a steady state, and in response to calcium or stimuli pauses.

CONCLUSIONS

The ST in infarcted rats increased the capacity to carry mass, associated with attenuation of cardiac remodeling and pulmonary congestion with improving cardiac function that could be attributed, at least in part, to the improvement of myocardial contractility.

Selective determination of ellagic acid in aqueous solution using blue-green emissive copper nanoclusters

Development of beneficial sensors to analyze ellagic acid concentrations is of great importance for food safety and human health. Herein, a facile and fast fluorescent probe was carried out for the excellently selective and sensitive measurement of ellagic acid in real samples through histidine protected copper nanoclusters (histidine@Cu NCs) as a nanosensor. This as-developed histidine@Cu NCs were performed through UV-vis absorption spectroscopy, fluorescence spectroscopy, transmission electron microscopy, Fourier-transform infrared spectroscopy, X-ray photoelectron spectroscopy and fluorescence lifetime analysis. The TEM image revealed that this nanomaterial had spherical features with the average diameter of 2.5 ± 0.05 nm. The blue-green fluorescence of this Cu NCs was found under the UV light. Meanwhile, the maximum excitation and emission wavelength were located at 387 nm and 488 nm. After addition of ellagic acid, the fluorescence of histidine@Cu NCs was slowly weakened with excellent linear range of 0.5-300 μM and detection limit of 0.077 μM. The fluorescence weakening mechanism of this nanosensor were attributed to the inner filter effect (IFE) and static quenching. Finally, this as-established analysis platform was successfully employed to measure ellagic acid in real samples.

Plasma metabolomic characterization of premature ovarian insufficiency

BACKGROUND

Premature ovarian insufficiency (POI) patients are predisposed to metabolic disturbances, including in lipid metabolism and glucose metabolism, and metabolic disorders appear to be a prerequisite of the typical long-term complications of POI, such as cardiovascular diseases or osteoporosis. However, the metabolic changes underlying the development of POI and its subsequent complications are incompletely understood, and there are few studies characterizing the disturbed metabolome in POI patients. The aim of this study was to characterize the plasma metabolome in POI by using ultrahigh-performance liquid chromatography-mass spectrometry (UHPLC-MS/MS) metabolomics and to evaluate whether these disturbances identified in the plasma metabolome relate to ovarian reserve and have diagnostic value in POI.

METHODS

This observational study recruited 30 POI patients and 30 age- and body mass index (BMI)-matched controls in the Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University, from January 2018 to October 2020. Fasting venous blood was collected at 9:00 am on days 2-4 of the menstrual cycle and centrifuged for analysis. An untargeted quantitative metabolomic analysis was performed using UHPLC-MS/MS.

RESULTS

Our study identified 48 upregulated and 21 downregulated positive metabolites, and 13 upregulated and 48 downregulated negative metabolites in the plasma of POI patients. The differentially regulated metabolites were involved in pathways such as caffeine metabolism and ubiquinone and other terpenoid-quinone biosynthesis. Six metabolites with an AUC value > 0.8, including arachidonoyl amide, 3-hydroxy-3-methylbutanoic acid, dihexyl nonanedioate, 18-HETE, cystine, and PG (16:0/18:1), were correlated with ovarian reserve and thus have the potential to be diagnostic biomarkers of POI.

CONCLUSION

This UHPLC-MS/MS untargeted metabolomics study revealed differentially expressed metabolites in the plasma of patients with POI. The differential metabolites may not only be involved in the aetiology of POI but also contribute to its major complications. These findings offer a panoramic view of the plasma metabolite changes caused by POI, which may provide useful diagnostic and therapeutic clues for POI disease.